<a href="https://www.fiercebiotech.com/biotech/pfizers-23b-trillium-bet-ends-failure-remaining-cd47-blocker-scrapped" hreflang="en">Pfizer’s $2.3B Trillium bet ends in failure as remaining CD47 blocker scrapped along with T-cell engager</a>
Pfizer has abandoned its $2.3 billion investment in Trillium Therapeutics by scrapping its last remaining CD47 blocker, maplirpacept, along with a T-cell engager and an acne treatment, citing business decisions rather than safety concerns. This decision reflects ongoing challenges in developing effective cancer therapies targeting the CD47 receptor, as no approved drugs currently exist in this category.
The key insight for you is the significant challenge and risk associated with targeting the CD47 receptor, as demonstrated by Pfizer's $2.3 billion Trillium acquisition leading to no viable therapies. This underscores the importance of thorough due diligence and strategic decision-making when investing in unproven therapeutic targets, particularly in competitive and high-stakes areas of drug discovery like oncology.